Clinical trials: High Risk Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept injectioN
To assess the safety and efficacy of intravitreal aflibercept injection in the regression of retinal neovascularization secondary to high-risk PDR.
- Trial name
- ELYSIAN (NCT02630277)
- Testing
- Aflibercept
- Volunteers
- 30 people
- Sponsor
- Valley Retina Institute
Proliferative Diabetic Retinopathy - High Risk
Ultra-Widefield Fluorescein Angiography-Based Targeted Retinal Photocoagulation Versus Conventional Panretinal Photocoagulation in the Preservation of Visual Function and Regression of Proliferative Diabetic Retinopathy
Proliferative diabetic retinopathy is a vision-threatening disease that can lead to irreversible visual loss. The treatment options for proliferative diabetic retinopathy are anti-VEGF injection and retinal photocoagulation.
- Trial name
- NCT06653361
- Testing
- Green laser
- Where
- Pakistan
- Volunteers
- 120 people
- Sponsor
- Hayatabad Medical Complex
Diabetic Macular Edema (DME)
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
Patients with diabetic macular edema (DME) sometimes must undergo vitrectomy surgery (PPV) for diabetic and non-diabetic related issues.
- Trial name
- NCT06662994
- Testing
- Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Retina Consultants of Orange County
Proliferative Diabetic Retinopathy - High Risk
Patient Comfort Using Green vs. Yellow Pan Retinal Photocoagulation
Our aim is to compare patient comfort when using the 532 nanometer (green) wavelength laser to the 577 nanometer (yellow) wavelength laser during pan retinal photocoagulation to treat patients with diabetic retinopathy.
- Trial name
- NCT02995629
- Testing
- laser indirect ophthalmoscopy pan retinal photocoagulation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wills Eye
Proliferative Diabetic Retinopathy - High Risk
Immediate Postoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy
Patients undergoing surgery for complications related to diabetes will be recruited.
- Trial name
- Postop IVA (NCT06899529)
- Testing
- Bevacizumab
- Where
- Mexico
- Volunteers
- 150 people
- Sponsor
- Christian Ophthalmic Surgery Expedition Network
Proliferative Diabetic Retinopathy (PDR)
High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes
The purpose of this Phase 4 study is to evaluate the safety of aflibercept 8mg in patients with proliferative diabetic retinopathy without center-involved diabetic macular edema.
- Trial name
- HERO (NCT07118670)
- Testing
- Aflibercept 8mg
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Edward Wood, MD
High Risk Proliferative Diabetic Retinopathy, Diabetes Mellitus Type I
Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.
To evaluate the safety and determine the efficacy of PRP monotherapy or combination therapy (pegaptanib 0.3 mg plus PRP) in patients with Type I or Type II diabetes mellitus and with high risk proliferative diabetic retinopathy.
- Conditions
- High Risk Proliferative Diabetic Retinopathy, Diabetes Mellitus Type I, Diabetes Mellitus Type II
- Trial name
- NCT01281098
- Testing
- Panretinal Photocoagulation (PRP), Intravitreous injection of pegaptanib
- Where
- Portugal
- Volunteers
- 22 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Pain
Oral Diclofenac for Retinal Photocoagulation in Diabetic Retinopathy
The purpose of this study was to evaluate the analgesic effect of oral potassium diclofenac in patients with proliferative diabetic retinopathy submitted to retinal photocoagulation.
- Trial name
- NCT01009021
- Testing
- potassium diclofenac
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- University of Sao Paulo
Diabetic Retinopathy, Retinal Detachment
Silicone Oil Versus Gas in PDR Patients Undergoing Vitrectomy
Subjects receiving 16% C3F8 gas tamponade during vitrectomy will have better visual acuity and similar postoperative complications to subjects who receive silicone oil tamponade during vitrectomy.
- Trial name
- NCT03660384
- Testing
- PPV/SO, PPV/C3F8
- Where
- Mexico
- Volunteers
- 302 people
- Sponsor
- Rush Eye Associates
High Risk Proliferative Diabetic Retinopathy
Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.
This study is a prospective, randomized, multicentre, open label study that intents to compare the efficacy and safety of ranibizumab 0.5 mg Intravitreal (ITV) injections plus Panretinal Photocoagulation versus Panretinal…
- Trial name
- PROTEUS (NCT01941329)
- Testing
- Panretinal Photocoagulation (PRP), Intravitreous injection of ranibizumab
- Where
- 13 sites in France, Italy and 2 more
- Volunteers
- 94 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
High Risk Proliferative Diabetic Retinopathy
Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy
The purpose of this trial is to evaluate safety and to compare the efficacy of intravitreous injection of ranibizumab alone (0.5 mg), versus combination of intravitreous injection of ranibizumab (0.5 mg) plus panretinal…
- Trial name
- NCT01280929
- Testing
- Panretinal Photocoagulation (PRP), Intravitreous injection of ranibizumab
- Where
- 7 sites in Portugal
- Volunteers
- 54 people
- Sponsor
- José Cunha-Vaz
Diabetic Retinopathy, Retinal Neovascularization
Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy
The purpose of this study is to evaluate the effects of panretinal photocoagulation plus intravitreal ranibizumab for the treatment of patients with high risk proliferative diabetic retinopathy in terms of changes in visual…
- Trial name
- IRaHi (NCT01102946)
- Testing
- Ranibizumab, Panretinal Photocoagulation
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- University of Sao Paulo
Diabetic Retinopathy
Evaluation of Doxycycline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy
This 24 month randomized research study will evaluate whether doxycycline can 1) slow the deterioration or improve retinal function and/or 2) induce regression, or slow progression, of diabetic retinopathy in participants over 18…
- Trial name
- POC1 (NCT00511875)
- Testing
- doxycycline monohydrate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Thomas Gardner